The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
.webp)
Ashley YocumThe AML Hub was pleased to speak with Ashley Yocum, The Leukemia & Lymphoma Society, Washington D.C., US, during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. We asked, What are the latest updates on the Beat AML trial from ASH 2024?
Beat AML trial: Updates from ASH 2024
Yocum begins by introducing the ongoing Beat AML Master trial (NCT03013998), a screening protocol to assign personalized treatments to patients with acute myeloid leukemia (AML) aged ≥60 years who are unfit for chemotherapy. Initially focused on the newly diagnosed population, the screening protocol has been expanded to include patients with relapsed/refractory (R/R) AML or high-risk myelodysplastic syndromes. Yocum describes the first of the trials in the R/R setting, evaluating lomonitinib (ZE46-0134), a selective FLT3-IRAK4 inhibitor, in patients >18 years with FLT3-mutated AML (NCT06399315).
Yocum explains that the Beat AML Master trial is additionally exploring triplet therapies based on venetoclax and azacitidine, and a substudy, OptiAML, is investigating shorter venetoclax exposure (14 days vs the FDA-approved 28 day-regimen) in combination with azacitidine and novel targeted therapies.
Finally, Yocum highlights the focus of the BEAT AML Master trial on more decentralized and patient-centric approaches, including wearable patches for monitoring vital signs.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
